Deng Lu, Zhang Xinyue, Dong Yan, Wang Lizhen, Chen Keling, Zheng Meiling, Yang Zidanqing, Tang Hui, Liao Wenhao, Shi Qunfeng
Hospital of Chengdu University of Traditional Chinese Medicine.
College of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Medicine (Baltimore). 2020 Oct 2;99(40):e22315. doi: 10.1097/MD.0000000000022315.
chronic obstructive pulmonary disease (COPD) is 1 of the leading causes of morbidity and mortality worldwide; its economic and social burdens are substantial and increasing. Recent years, an increasing number of study has shown the promising advantage of Erchen decoction (ECD) combined with sanziyangqin decoction (SZYQD) in treating COPD. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to provide a protocol for a systematic review on ECD combined with SZYQD for COPD and provide effective evidence for further clinical use.
We will conduct a Computerized literature searches in the following databases: PubMed, MEDLINE, EMBASE, Cochrane Library, China national information network, China biomedical literature database (CBM), Chinese Scientific Journals Database and wanfang database, from their inception to June 2020, without restrictions of language. Study selection, data collection, and evaluation of the quality of evidence will be performed by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0.
This study will systematically evaluate the effectiveness and safety of ECD combined with SZYQD for COPD. The results will be published in a peer-reviewed journal.
This study will provide evidence from the current published RCTs of whether ERD combined with SZYQD is an effective and safe intervention for COPD.
This study is a systematic review, the outcomes are based on the published evidence. In this study, no individual data from participants will be involved, so ethics approval is not required.
OPEN SCIENCE FRAMEWORK(OSF)REGISTRATION NUMBER: August 19, 2020; osf.io/zxm24.
慢性阻塞性肺疾病（COPD）是全球发病和死亡的主要原因之一；其经济和社会负担巨大且呈上升趋势。近年来，越来越多的研究表明二陈汤（ECD）联合三子养亲汤（SZYQD）治疗COPD具有显著优势。然而，由于缺乏证据，尚无具体方法或建议，因此有必要提供一份关于ECD联合SZYQD治疗COPD的系统评价方案，为进一步临床应用提供有效证据。
我们将在以下数据库进行计算机化文献检索：PubMed、MEDLINE、EMBASE、Cochrane图书馆、中国国家信息网络、中国生物医学文献数据库（CBM）、中国科学期刊数据库和万方数据库，检索时间从建库至2020年6月，无语言限制。研究筛选、数据收集以及证据质量评估将由两名研究人员独立进行，荟萃分析的偏倚风险将根据《Cochrane干预措施系统评价手册》进行评估。所有数据分析将使用数据统计软件Review Manager V.5.3和Stata V.12.0进行。
本研究将系统评价ECD联合SZYQD治疗COPD的有效性和安全性。结果将发表在同行评审期刊上。
本研究将从当前已发表的随机对照试验中提供证据，证明二陈汤联合三子养亲汤对COPD是否为有效且安全的干预措施。
本研究为系统评价，结果基于已发表的证据。本研究不涉及参与者的个体数据因此无需伦理批准。
开放科学框架（OSF）注册号：2020年8月19日；osf.io/zxm24。
